SpaceX Stock Just Dropped Below Its Debut Price. Is the Stock a Buy?

SpaceX’s IPO opened at $150 and peaked around $225 before falling to about $145 per share, but the article argues the stock still looks too expensive versus its valuation of ~$2.1T. The bullish case cites fully reusable Starship lowering space-travel costs and Starlink’s momentum, including a regulatory request for 100,000 Gen3 satellites to boost capacity/speeds. Offsetting risks include heavy ongoing capital spending, potential regulatory delays for Starship, slower development timelines, and intensifying competition—leading the author to conclude it’s not a buy yet unless shares fall further.

Analysis

This is less a business update than a valuation stress test: the equity is being priced as if multiple long-dated options will clear simultaneously, so the first disappointment should show up as multiple compression rather than an immediate fundamental reset. In that setup, the stock is vulnerable to a 1-3 month de-rating if regulatory approvals or launch timelines slip, because there is no near-term earnings stream to cushion sentiment.

The real second-order loser is not the launch ecosystem but legacy connectivity. If low-orbit capacity scales the way bulls expect, the pressure lands on IRDM and VSAT first: pricing power erodes, churn rises, and customer acquisition costs increase as the market shifts from niche coverage to broadband substitution. AMZN’s Kuiper becomes a more expensive strategic response, not a direct winner, because SpaceX’s faster cadence raises the bar on capex efficiency and time-to-service.

Contrarian take: the market may be underestimating how much of the current valuation is already a “best-case regulatory + execution” bundle. That said, this is not a clean short if there are no borrowable public comparables tied tightly enough to the thesis; the better trade is to fade the most exposed listed proxies on strength and keep powder dry until one of the key milestones is actually missed. The thesis breaks if Starship licensing accelerates and Gen3 approvals arrive on schedule, because then the optionality stack becomes less speculative and more monetizable.

Key Decisions for Investors

• No immediate long in SPCX at current levels; require either a 20%+ retrace or verified progress on Starship licensing / Gen3 satellite approvals before reconsidering exposure.
• Short IRDM or VSAT on any 1-3 month rally; use them as the cleanest public-market proxies for Starlink-driven pricing pressure. Stop if regulatory approval stalls for two consecutive quarters.
• If you want a relative-value expression, pair short VSAT vs. long AMZN only as a small satellite-connectivity hedge; the goal is to own the stronger balance sheet while fading the most margin-sensitive incumbent.
• Set an alert on launch/regulatory milestones rather than price: if approvals slip by more than one quarter, expect another leg down in speculative space-adjacent names and a broader de-rating of pre-profit growth IPOs.